Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1B1 | P15121 | 1/20 | 0.43 |
| ▸ | PTGS1 | P23219 | 5/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 5/20 | 0.40 |
| ▸ | GSK3A | P49840 | 3/20 | 0.40 |
| ▸ | GSK3B | P49841 | 3/20 | 0.40 |
| ▸ | MGLL | Q99685 | 7/20 | 0.38 |
| ▸ | BLM | P54132 | 4/20 | 0.38 |
| ▸ | LMNA | P02545 | 3/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | FAAH | O00519 | 3/20 | 0.38 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.38 |
| ▸ | GABRR2 | P28476 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | GMNN | O75496 | 1/20 | 0.38 |
| ▸ | THPO | P40225 | 1/20 | 0.38 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.38 |
| ▸ | GABRR3 | A8MPY1 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | APEX1 | P27695 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27601261 | 0.82 | GSK3A (0.39) | AKR1B1PTGS1PTGS2GSK3AGSK3B | |
| Maleic Acid SCHEMBL10339012 | 0.78 | MGLL (0.52) | PTGS1PTGS2GSK3AGSK3BMGLL | |
| SCHEMBL822301 | 0.76 | MGLL (0.42) | PTGS1PTGS2GSK3AGSK3BMGLL | |
| SCHEMBL10713815 | 0.73 | CA12 (0.55) | AKR1B1NPSR1ALDH1A1MAPTRAB9A | |
| SCHEMBL10713825 | 0.73 | CA12 (0.55) | AKR1B1NPSR1ALDH1A1MAPTRAB9A | |
| SCHEMBL1955696 | 0.71 | MGLL (0.42) | PTGS1PTGS2GSK3AGSK3BMGLL | |
| SCHEMBL3813599 | 0.71 | MGLL (0.44) | PTGS1PTGS2GSK3AGSK3BMGLL | |
| SCHEMBL6537077 | 0.71 | MGLL (0.48) | PTGS1PTGS2GSK3AGSK3BMGLL | |
| SCHEMBL9414034 | 0.71 | MGLL (0.42) | PTGS1PTGS2GSK3AGSK3BMGLL | |
| SCHEMBL9181540 | 0.71 | MGLL (0.48) | PTGS1PTGS2GSK3AGSK3BMGLL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3620177-A1 | MODIFIED BLOOD FACTORS COMPRISING A LOW DEGREE OF WATER SOLUBLE POLYMER | Baxalta GmbH (CH) | 2020-03-11 | — | — | EP | disclosed |
| US-20190160178-A1 | MODIFIED BLOOD FACTORS COMPRISING A LOW DEGREE OF WATER SOLUBLE POLYMER | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-05-30 | — | — | US | disclosed |
| EP-3437661-A1 | MODIFIED BLOOD FACTORS COMPRISING A LOW DEGREE OF WATER SOLUBLE POLYMER | Baxalta GmbH (CH) | 2019-02-06 | — | — | EP | disclosed |
| EP-2349342-B1 | MODIFIED BLOOD FACTORS COMPRISING A LOW DEGREE OF WATER SOLUBLE POLYMER | Baxalta GmbH (CH) | 2018-06-27 | — | — | EP | disclosed |
| US-20170227557-A1 | METHOD AND COMPOSITIONS FOR SPECIFICALLY DETECTING PHYSIOLOGICALLY ACCEPTABLE POLYMER MOLECULES | BAXTER HEALTHCARE SA (CH) | 2017-08-10 | — | — | US | disclosed |
| US-9547016-B2 | Method and compositions for specifically detecting physiologically acceptable polymer molecules | BAXALTA INCORPORATED (US) | 2017-01-17 | — | — | US | disclosed |
| US-20160199503-A1 | MODIFIED BLOOD FACTORS COMPRISING A LOW DEGREE OF WATER SOLUBLE POLYMER | BAXTER INTERNATIONAL INC. | 2016-07-14 | — | — | US | disclosed |
| US-9274122-B2 | Methods for determining active ingredients in pro-drug PEG protein conjugates with releasable PEG reagents (in vitro de-pegylation) | BAXALTA INCORPORATED (US) | 2016-03-01 | — | — | US | disclosed |
| US-20140051094-A1 | Method and Compositions for Specifically Detecting Physiologically Acceptable Polymer Molecules | BAXTER HEALTHCARE SA (CH) | 2014-02-20 | — | — | US | disclosed |
| US-8557534-B2 | Method and compositions for specifically detecting physiologically acceptable polymer molecules | BAXTER INTERNATIONAL INC. (US) | 2013-10-15 | — | — | US | disclosed |
| EP-1597299-A2 | CARBONATE ESTERS OF POLYETHYLENE GLYCOL ACTIVATED BY MEANS OF OXALATE ESTERS | Pharmacia Corporation (US) | 2005-11-23 | — | — | EP | disclosed |
| US-20040242854-A1 | Chemical capture reagent | GE HEALTHCARE UK LIMITED (GB) | 2004-12-02 | — | — | US | disclosed |
| WO-2004074345-A2 | CARBONATE ESTERS OF POLYETHYLENE GLYCOL ACTIVATED BY MEANS OF OXALATE ESTERS | PHARMACIA CORPORATION (US) | 2004-09-02 | — | — | WO | disclosed |
| US-20040162388-A1 | Activated polyethylene glycol esters | PHARMACIA CORPORATION | 2004-08-19 | — | — | US | disclosed |
| EP-1402268-A2 | CHEMICAL CAPTURE REAGENT | Amersham Biosciences UK Limited (GB) | 2004-03-31 | — | — | EP | disclosed |
| US-20040029207-A1 | Compositions and methods for detecting and quantifying COX-2 activity by lipoamino acid metabolism | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2004-02-12 | — | — | US | disclosed |
| WO-2003014699-A2 | COMPOSITIONS AND METHODS FOR DETECTING AND QUANTIFYING COX-2 ACTIVITY BY LIPOAMINO ACID METABOLISM | VANDERBILT UNIVERSITY (US) | 2003-02-20 | — | — | WO | disclosed |
| WO-2003005026-A2 | CHEMICAL CAPTURE REAGENT | AMERSHAM BIOSCIENCES UK LIMITED (GB) | 2003-01-16 | — | — | WO | disclosed |
| JP-2002256025-A | METHOD FOR PRODUCING AQUEOUS POWDER SLURRY COMPOSITION | DAINIPPON INK & CHEM INC | 2002-09-11 | — | — | JP | disclosed |
| EP-0847991-A1 | Method for the preparation of N-(carboxyalkyl) imides | DAINIPPON INK AND CHEMICALS, INC. (JP) | 1998-06-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040162388-A1 | Activated polyethylene glycol esters | ACP1, FGF23, ACP3 | AKR1B1 3723/4885PTGS1 1403/4885PTGS2 2029/4885 |
| US-20040242854-A1 | Chemical capture reagent | SPPL2B, PRXL2A, PLG | AKR1B1 1893/4885PTGS1 1219/4885PTGS2 2425/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.